AJP - Regu Watch the video to see how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 294: R1498-R1503, 2008. First published March 12, 2008; doi:10.1152/ajpregu.00897.2007
0363-6119/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/5/R1498    most recent
00897.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Ray, R.
Right arrow Articles by Meldrum, D. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ray, R.
Right arrow Articles by Meldrum, D. R.

TRANSLATIONAL PHYSIOLOGY

Deleterious effects of endogenous and exogenous testosterone on mesenchymal stem cell VEGF production

Rinki Ray,1 Christine M. Herring,1 Troy A. Markel,1 Paul R. Crisostomo,1 Meijing Wang,1 Brent Weil,1 Tim Lahm,3 and Daniel R. Meldrum1,2,4

Departments of 1Surgery, 2Cellular and Integrative Physiology, and 3Pulmonary and Critical Care Medicine and 4Center for Immunobiology, Indiana University School of Medicine, Indianapolis, Indiana

Submitted 14 December 2007 ; accepted in final form 11 March 2008

ABSTRACT

Modulating the paracrine effects of bone marrow mesenchymal stem cells (BMSCs) may be important for the treatment of ischemic myocardial tissue. In this regard, endogenous estrogen may enhance BMSC vascular endothelial growth factor (VEGF) production. However, little information exists regarding the effect of testosterone on stem cell function. We hypothesized that 1) endogenous or exogenous estrogen will enhance stem cell production of VEGF and 2) endogenous or exogenous testosterone will inhibit BMSC VEGF production. BMSCs were collected from adult male, female, castrated male, and ovariectomized female rats. One hundred thousand cells were incubated with testosterone (1, 10, or 100 nM) or estrogen (0.15, 1.5, or 15 nM) for 48 h. Cell supernatants were collected, and VEGF was measured by ELISA. BMSCs harvested from castrated males, normal females, and ovariectomized females produced more VEGF compared with normal males. Castration was associated with the highest level (1,018 ± 98.26 pg/ml) of VEGF production by BMSCs, which was significantly more than that produced by BMSCs harvested from normal male and normal female animals. Exogenous testosterone significantly reduced VEGF production in BMSCs harvested from ovariectomized females in a dose-dependent manner. Exogenous estrogen did not alter BMSC VEGF production. These findings suggest that testosterone may work on BMSCs to decrease protective growth factor production and that effective removal of testosterone's deleterious effects via castration may prove to be beneficial in terms of protective factor production. By manipulating the mechanisms that BMSCs use to produce growth factors, we may be able to engineer stem cells to produce maximum growth factors during therapeutic use.

sex; sex hormones; estrogen; castration; ovariectomy; androgens



Address for reprint requests and other correspondence: D. R. Meldrum, 2017 Van Nuys Medical Science Bldg., 635 Barnhill Dr., Indianapolis, IN 46202 (e-mail: dmeldrum{at}iupui.edu)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.